Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines-Reference-Cited by-同舟云学术

Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines

Published:2021-05 Issue:5 Volume:6 Page:e005912
ISSN:2059-7908
Container-title:BMJ Global Health
language:en
Short-container-title:BMJ Glob Health

Author:

Wolff Jonathan^ORCID,Atuire Caesar,Bhan Anant,Emanuel Ezekiel,Faden Ruth,Ghimire Prakash^ORCID,Greco Dirceu,Ho Calvin W L^ORCID,Kochhar Sonali,Moon Surie,Schaefer Owen G^ORCID,Shamsi-Gooshki Ehsan,Singh Jerome Amir,Smith Maxwell J^ORCID,Thomé Beatriz,Touré Aissatou,Upshar Ross

Publisher

BMJ

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference7 articles.

1. Strategic Advisory group of experts on immunization (SAGE). Available: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials

2. Evidence to recommendations for COVID-19 vaccines: evidence framework. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-SAGE-Framework-Evidence-2020-1

3. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19. Available: https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19

4. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1

5. Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca: interim guidance, 2021. Available: https://apps.who.int/iris/handle/10665/339477

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial;PLOS Global Public Health;2022-12-20

2. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project;Frontiers in Immunology;2022-08-29

3. COVID-19 vaccination challenges: A mini-review;Human Vaccines & Immunotherapeutics;2022-05-05

4. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial;2022-03-31

5. Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19;npj Vaccines;2021-11-04